Opinion|Videos|August 12, 2024
Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing
Key opinion leaders examine recent evidence on acquired BTK inhibitor resistance in chronic lymphocytic leukemia and analyze its implications for treatment sequencing decisions in clinical practice.
Advertisement
Episodes in this series
- Briefly discuss the latest evidence surrounding acquired BTKi resistance in CLL. What clinical insights do recent data provide?
- DrDAVIDS:ELEVATE-RR –
Woyach J et al. ICML 2023. Abstract 163 ;Poster 163 - (57:40 – follow up Q) invitro datanot hte end all be all.
- DrDAVIDS:ELEVATE-RR –
Dr Coombs to Group:What implications may these findings have on treatment sequencing? Is there a potential role of testing for acquired mutations upon disease progression?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 that may shake up the CLL treatment paradigm.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
4
How Are Treatment Intensification and Sequencing Reshaping Care in Prostate Cancer and RCC
5